GLP-1s Have Protective Benefit Against DME, Glaucoma Surgery
Recent research presented at the American Academy of Ophthalmology suggests that GLP-1 receptor agonists may offer protective benefits against diabetic macular edema and reduce the need for glaucoma surgery. The studies compared these outcomes against patients using metformin.
Why it matters
These findings could influence treatment protocols for diabetic patients, potentially improving long-term ocular health outcomes.
Posters presented during the American Academy of Ophthalmology 2026 Annual Meeting, held in New Orleans, Louisiana, from October 10-12, detailed the potential benefits of glucagon-like peptide-1 receptor agonists (GLP-1RA), with reduced incidence of diabetic macular edema (DME) among patients, as well as reduced need for glaucoma surgery when receiving the treatment.
Incidence of DME Reduced in Patients With Diabetic Retinopathy
In the first poster,1 the researchers aimed to evaluate DME development in patients who had previously been diagnosed with diabetic retinopathy (DR). Outcomes were compared between patients who were taking metformin and patients who were taking a GLP-1RA.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in